Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study.
Fiche publication
Date publication
août 2019
Journal
Arthritis & rheumatology (Hoboken, N.J.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M,
Lien Pubmed
Résumé
Immune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune Related Adverse Effects (IRAE). Therefore, most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. This study aims to evaluate the safety and efficacy of ICI in patients with PAD and cancer.
Mots clés
autoimmune disease, cancer, immune checkpoint inhibitors, immune-related adverse events, immunotherapy